These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with no track record or liquidity, and...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with no track record or liquidity, and...
When one of the biggest and most populated states decides it is time to legalize pot, it is also time for investors to look at the top stocks in the industry again. Many of them have backed up...
Seven heavily traded companies will be reporting quarterly earnings Thursday after markets close and before they open again Friday morning. Here's a look at what to expect.
London-based Jazz Pharmaceuticals has agreed to pay $7.2 billion to acquire GW Pharmaceuticals, a maker of drugs derived from cannabis plants.
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
These are five stocks for aggressive investors that look to get share count leverage on companies that have sizable upside potential. They could prove exciting additions to portfolios, and major Wall...
Late last week, some top pot stocks rallied. We screened the 24/7 Wall St. research database looking for marijuana stocks that could offer investors some huge returns over the next year or so and...
A new report projects sales of hemp-derived CBD products could rise to around $1.8 billion in 2020, on their way to a rise of more than three times by 2025.
Canada-based medical and recreational marijuana company Aurora Cannabis announced Monday that it has a new CEO and will take a substantial write-down on goodwill and other intangible assets.
A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.
A recent final ruling from the U.S. Drug Enforcement Administration has cast doubt on the legality of some non-psychoactive products derived from the hemp.
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
A labeling requirement in California warning consumers of the risks of products derived from cannabis could have a chilling effect on the state's legal growers and retailers.
There may be a new dawn for Aurora Cannabis as online sales rise, new retail outlets open, and Reliva deal offers access to U.S. market.